Aspirin and blood pressure: Effects when used alone or in combination with antihypertensive drugs

Ana Catarina Costa1, Marta Reina-Couto2, António Albino-Teixeira3

  • 1Departamento de Biomedicina - Unidade de Farmacologia e Terapêutica, Faculdade de Medicina da Universidade do Porto, Porto, Portugal.

Insights

Low-dose aspirin

Area of Science:

  • Cardiovascular medicine and pharmacology.
  • Renal physiology and hypertension.
  • Inflammation and lipid mediator biology.

Background:

  • Arterial hypertension is a significant risk factor for cardiovascular and renal diseases.
  • Low-dose aspirin is widely used for cardiovascular event prevention, often combined with antihypertensive drugs.
  • The effect of aspirin on blood pressure control is debated, with potential benefits and drawbacks.

Purpose of the Study:

  • To review the multifaceted effects of aspirin on blood pressure.
  • To elucidate the mechanisms underlying aspirin's impact on blood pressure, including novel pathways.
  • To examine the interactions between aspirin and antihypertensive medications.

Main Methods:

  • Review of experimental and human studies on aspirin and hypertension.
  • Analysis of aspirin's effects on blood pressure regulation and cardiovascular outcomes.
  • Investigation of aspirin's influence on specialized pro-resolving lipid mediators and inflammation.

Main Results:

  • Aspirin's cardioprotective effects may involve more than antithrombotic actions, including anti-inflammatory and pro-resolving pathways.
  • Aspirin can improve vasodilation via cyclooxygenase-independent mechanisms.
  • Higher aspirin doses may negatively impact blood pressure by inhibiting cyclooxygenase-2, reducing renal function.

Conclusions:

  • Aspirin's net effect on blood pressure is complex and dose-dependent.
  • Understanding aspirin's interaction with antihypertensive drugs is crucial for optimizing patient care.
  • Novel mechanisms involving lipid mediators contribute to aspirin's vascular effects.

Related Concept Videos

Drug toxicity: Drug–Drug Interaction01:30

Drug toxicity: Drug–Drug Interaction

Drug–drug interactions can precipitate toxicity through multiple mechanisms. Absorption interactions alter how drugs enter the body, exemplified when ranitidine increases the absorption of basic drugs, while cholestyramine decreases the levels of propranolol. Protein binding interactions occur when drugs share the same binding sites on plasma proteins. Drugs like aspirin and warfarin, when bound in excess, can lead to increased free drug concentrations, enhancing the potential for...
108
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
2.9K
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
1.6K
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
2.7K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.3K
Antianginal Drugs: Nitrates and β-Blockers01:16

Antianginal Drugs: Nitrates and β-Blockers

In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates,  such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
1.8K